Loading...
XSTO
ISOFOL
Market cap22mUSD
Dec 05, Last price  
0.74SEK
1D
0.41%
1Q
-9.38%
IPO
-97.22%
Name

Isofol Medical AB (publ)

Chart & Performance

D1W1MN
XSTO:ISOFOL chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
23.33%
Rev. gr., 5y
-11.85%
Revenues
0k
-100.00%
0187,000508,000227,0000037,119,00022,407,00012,797,000721,0000
Net income
-43m
L+17.31%
-10,601,308-40,689,000-64,018,000-72,035,000-83,125,000-157,231,000-188,992,000-196,884,000-155,943,000-37,071,000-43,488,000
CFO
-42m
L-20.08%
0-36,767,000-56,902,000-61,943,000-92,458,000-147,208,000-160,270,000-188,429,000-190,975,000-52,536,000-41,986,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
URL
https://isofolmedical.com/
IPO date
Apr 04, 2017
Employees
3
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT